Rights to Schizophrenia Drug Worth up to $702M for Addex Jan. 4, 2008 By Donna Young Swiss biotech Addex Pharmaceuticals has granted rights to Merck & Co. Inc. to develop ADX63365, an investigational treatment for schizophrenia, in a deal potentially worth $702 million. (BioWorld Today)Read More
Washington roundup: CBO says inflation, not aging, is largest Medicare cost driver Jan. 4, 2008 By Mark McCarty
RSS